Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Decitabine
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia, Adult
1 trial -
Decitabine plus HAAG regimen
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF
Hospital Authority, Hong Kong
Acute Myeloid Leukemia
1 trial -
Deflazacort
PTC THERAPEUTICS, INC.
Limb-Girdle Muscular Dystrophy
1 trial -
Delayed and extended release mesalazine
Takeda
Colitis, Ulcerative
1 trial -
Depigoid Grass-Mix (1000 DPP/ml), Conjunctival Provocation Test Grass-Mix LETI 30 HEP/ml, The placebo to be used in the clinical trial is the solvent used in the investigational medicinal products’ (IMPs) formulation. The resulting product is a suspension., Depigoid FORTE Grass-Mix (3000 DPP/ml)
Lacuna Pharma Pty Ltd
Allergic rhinoconjunctivitis with or without controlled asthma
1 trial -
Deucravacitinib placebo 3 mg film-coated tablets oral use, Deucravacitinib placebo 6 mg film-coated tablets oral use, deucravacitinib, deucravacitinib
Bristol-Myers Squibb Australia Pty Ltd
Sjogren's syndrome
1 trial -
Dexa 8 mg inject JENAPHARM Injektionslösung, VELCADE 3.5 mg powder for solution for injection, Dexamethason 8 mg GALEN® Tabletten, Dexamethasone Tablets BP 2.0mg, Dexamethasone 2mg Tablets, Dexa-ratiopharm® 8 mg Injektionslösung, DARZALEX 20 mg/mL concentrate for solution for infusion, Dexamethason 8 mg JENAPHARM®
GlaxoSmithKline
Multiple Myeloma
1 trial -
Dexamethason 8 mg GALEN® Tabletten, Imnovid 1 mg hard capsules, Dexamethasone 2mg Tablets, Dexamethason 8 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, Imnovid 4 mg hard capsules
GlaxoSmithKline
Relapsed/Refractory Multiple Myeloma
1 trial -
Dexamethason CF 20 mg/ml, injectievloeistof, Imnovid 4 mg hard capsules, ELOTUZUMAB, VELCADE 3.5 mg powder for solution for injection, IXAZOMIB , Dexamethason 4 mg JENAPHARM®, Kyprolis 30 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Revlimid 15 mg hard capsules, IXAZOMIB, idecabtagene vicleucel, DARZALEX 20 mg/mL concentrate for solution for infusion, Revlimid 10 mg hard capsules, IXAZOMIB, Revlimid 5 mg hard capsules, Revlimid 25 m
Celgene Europe Limited
Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.
1 trial -
Dexamethasone
Amgen
Relapsed Multiple Myeloma
1 trial -
Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Lenalidomide Accord 15 mg hard capsules, CARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion, Lenalidomide Mylan 5 mg hard capsules, Lenalidomide Mylan 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Mylan 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, FLUDARABINE , Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 10 mg hard capsules
Janssen-Cilag International N.V.
Multiple Myeloma
1 trial -
Dexlansoprazole
Takeda
Heartburn
1 trial -
Dexlansoprazole
Takeda
Gastroesophageal Reflux
2 trials -
Dexlansoprazole
Takeda
Erosive Esophagitis
2 trials -
Dexlansoprazole MR
Takeda
Esophagitis, Reflux
5 trials -
Dexlansoprazole MR
Takeda
Gastroesophageal Reflux Disease
4 trials -
Dexlansoprazole MR QD
Takeda
Gastroesophageal Reflux
1 trial -
Dexmedetomidine 100 micrograms/ml concentrate for solution for infusion, Midazolam Lek 1 mg/ml raztopina za injiciranje/infundiranje
Tour Hekla
Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care:
1 trial -
Diacomit 250 mg hard capsules, Matched Placebo will consist in caspules similar to the 250 and 500 mg capsules of stiripentol but with no active ingredient, Diacomit 500 mg hard capsules
Biocodex
Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)
1 trial -
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category
Aquestive Therapeutics
Epilepsy
1 trial -
Diflucan 200mg Hard Capsules, PLACEBO to Posaconazol hexal, Posaconazol HEXAL 100 mg, NOXAFIL® (posaconazole) Injection, Placebo to bactrim, diflucan 200 mg - microcrystalline cellulose capsules, DIFLUCAN INJECTION, REZZAYO 200 mg powder for concentrate for solution for infusion, Saline solution, REZZAYO 200 mg powder for concentrate for solution for infusion, Bactrim Tablets, NOXAFIL® (posaconazole) Delayed-Release Tablets
Mundipharma Pty Limited
Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Marrow Transplantation (BMT)
1 trial -
Dipyridamole 50mg tid
The First People's Hospital of Lianyungang
Restless Leg Syndrome Due to Uraemia
1 trial -
Distress Thermometer and Problems List
United Therapeutics Europe Ltd
Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources